Innovent Biologics, Inc.

In a marked departure from its established business model of in-licensing external assets, Zai Lab is now pulling off a crossover into the self-discovery of first-in-class molecules. The biopharma com

Shanghai Henlius Biotech is trying to play a David versus Goliath game of catch-up with Pfizer, in pursuit of the commercialization of the world’s first PD-L1-targeting antibody-drug conjugate (ADC).

Jiangsu Hengrui Pharmaceuticals, China’s top innovative drug maker by pipeline size, is set to spring back into the high-stakes arena of global Phase III clinical trials which include sites in the US

Taiho Pharmaceuticals said on 17 March that it will spend $400m up front and up to $740m in milestone payments to expand its cancer drug development pipeline through the acquisition of antibody-drug c